Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, First-in-human, Open-label Dose Escalation and Cohort Expansion Study of KB-0742 in Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma

NCT04718675 is registered in ClinicalTrials.gov with Kronos Bio as lead sponsor.

NCT NCT04718675
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04718675 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, First-in-human, Open-label Dose Escalation and Cohort Expansion Study of KB-0742 in Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma
Lead sponsor
Kronos Bio
Phase
Phase 1/2
Overall status
Terminated
Start date
February 8, 2021
Completion date
February 7, 2025
Enrollment
135 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

hgsoc, non-hodgkin lymphoma, platinum resistant high grade serous ovarian cancer, refractory solid tumors, relapsed solid tumors